

## Anika to Issue Third-Quarter 2017 Financial Results and Business Highlights on Wednesday, October 25

BEDFORD, Mass.--(BUSINESS WIRE)-- <u>Anika Therapeutics</u>, <u>Inc.</u> (NASDAQ: ANIK) today announced that the Company plans to issue its third-quarter 2017 financial results after the close of the market on Wednesday, October 25, 2017 and to hold a conference call the next day, Thursday, October 26, 2017, at 9:00 a.m. ET to discuss its financial results, business highlights, and outlook.

The conference call can be accessed by dialing 1-855-468-0611 (toll-free domestic) or 1-484-756-4332 (international). A live audio webcast will be available in the "Investor Relations" section of Anika's website, <a href="www.anikatherapeutics.com">www.anikatherapeutics.com</a>. An accompanying slide presentation also can be accessed via the Anika Therapeutics website. The call will be archived and accessible on the same website shortly after its conclusion.

About Anika Therapeutics, Inc.

Anika Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated orthopedic medicines company based in Bedford, Massachusetts. Anika is committed to improving the lives of patients with degenerative orthopedic diseases and traumatic conditions with clinically meaningful therapies along the continuum of care, from palliative pain management to regenerative cartilage repair. The Company has over two decades of global expertise developing, manufacturing, and commercializing more than 20 products based on its proprietary <a href="https://pyscholor.org/hyaluronic acid (HA) technology">hyaluronic acid (HA) technology</a>. Anika's orthopedic medicine portfolio includes <a href="https://pyscholor.org/hyaluronic acid (HA) technology">ORTHOVISC®</a>, <a href="https://pyscholor.org/monotonic acid (HA) technology</a>, Anika's orthopedic medicine portfolio includes <a href="https://pyscholor.org/hyaluronic acid (HA) technology</a>, Anika's orthopedic medicine portfolio includes <a href="https://pyscholor.org/hyaluronic acid (HA) technology</a>, and <a href="https://pyscholor.org/hyaluronic acid (HA) technol

View source version on businesswire.com: http://www.businesswire.com/news/home/20171011006198/en/

For Investor Inquiries: Anika Therapeutics, Inc. Sylvia Cheung, Chief Financial Officer Tel: 781.457.9000 or For Media Inquiries: Pure Communications

Sonal Vasudev Tel: 917.523.1418

Source: Anika Therapeutics, Inc.
News Provided by Acquire Media

https://ir.anika.com/Anika-to-Issue-Third-Quarter-2017-Financial-Results-and-Business-Highlights-on-Wednesday,-October-25